Pharmacogenetics to Avoid Adverse Drug Reactions
López-Fernández, Luis A. (editor)
Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.
Keywords5-fluorouracil; capecitabine; fluoropyrimidine; thymidylate synthase; thymidylate synthase enhancer region; upstream stimulatory factor 1; adverse drug reactions; pharmacogenomics; epistasis; random forest; statin; cardiovascular disease; colorectal cancer; personalised medicine; toxicity; (es)citalopram; drug-gene-interaction; drug-drug-interaction; drug-drug-gene-interaction; the PharmLines initiative; antipsychotic agents; pharmacogenetics; cytochrome P-450 enzyme system; psychotic disorders; precision medicine; direct oral anticoagulants; clinical implementation; atorvastatin; SLCO1B1; HLA; cutaneous adverse drug reaction; SCAR; genetic polymorphism; antiepileptics; CYP450 enzymes; platelet reactivity; single-nucleotide variants; acute coronary syndrome; clopidogrel; genotype; allele; polymorphism; HLA B; CYP2C9*3; cutaneous adverse drug reactions (CADRs); anti-epileptic drugs (AEDS); phenytoin (PHT); genetic risk factors; South India; India; cardiology; adverse events; guidelines; n/a
Webshop linkhttps://mdpi.com/books/pdfview ...
Publication date and placeBasel, 2022